Category - Drug discovery

The Multifaceted and Sometimes Paradoxical Nature of Reactive Oxygen Species in Cancer

TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.

Novel Genetic Priority Score (GPS) Unveiled to Enhance Target Prioritization in Drug Development

The FDA’s Center for Drug Evaluation and Research (CDER) Approved 55 New Drugs in 2023

L7 Informatics Manages and Supports the Entire Lab Workflow from Sample Processing to Data Analysis and Insight Generation Employing Workflow Orchestration

The Role of the Human Gut Microbiome in Alzheimer’s Disease Development

Velsera Is Building an Ecosystem that Accelerates the R&D Loop and Democratizes Omics Data to Propel the Next Era of Precision Medicine

ONTOFORCE Wants to Increase Data Literacy and Empower Citizen Data Scientists

Deepcell Aims to Create a Single Cell Morpholome Platform

We Invite you to join enlightenbio’s Subject Matter Expert Network!

Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

FAIR Data or the Journey Towards Data-Centricity – Pushing Towards Making Data Discoverable, Accessible, Interoperable, and Reusable

GATC Health and Liquid Biosciences Partner to Improve Drug Development & Precision Medicine Research

Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)

Copyright © 2026. enlighenbio LLC. All rights reserved.